News | October 29, 2021
Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Filing marks first protein-based vaccine submitted to MHRA for authorization
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Since its inception, the company has either acquired or taken a majority stake in five companies
The investment will increase SpeeDx internal capacity to scale up manufacturing
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Domestic business was up 41.9% YoY and 27.7% QoQ
Subscribe To Our Newsletter & Stay Updated
